Poold Diagnostics

Company Overview

Snapshot

Founded in July 2020 by Prof. Tomer Hertz, Dr. Noam Shental, and Prof. Angel Porgador, Poold Diagnostics operates with 1–10 employees. The company's method for high-throughput SARS-CoV-2 testing was approved for clinical use by the Israeli Ministry of Health in August 2020.

Business overview

Poold Diagnostics specializes in developing high-throughput diagnostic testing methods, primarily for SARS-CoV-2. The company's core technology, the pooling-based efficient SARS-CoV-2 testing (P-BEST) method, leverages PCR and a combinatorial pooling algorithm based on compressed sensing theory. This innovation enables diagnostic laboratories to significantly increase testing capacity and reduce costs by identifying positive subjects within large sample sets using a single round of testing. Poold Diagnostics operates within the Health Tech & Life Sciences sector, serving the healthcare industry, particularly laboratories, with solutions in digital medical diagnostics and medical decision support.

Strategic signal

In August 2020, Poold Diagnostics' P-BEST method received approval for clinical use from the Israeli Ministry of Health. This validation is a significant signal of the technology's efficacy and readiness for real-world application, demonstrating its potential to enhance diagnostic capabilities for infectious diseases and offering a scalable solution for public health challenges.

Company Intelligence Q&A

What is Poold Diagnostics' primary focus?

Poold Diagnostics focuses on developing high-throughput diagnostic testing methods, specifically for large-scale identification of asymptomatic carriers of COVID-19.

When was Poold Diagnostics founded and by whom?

Poold Diagnostics was founded in July 2020 by Prof. Tomer Hertz, Dr. Noam Shental, and Prof. Angel Porgador.

What is the P-BEST method?

The P-BEST (pooling-based efficient SARS-CoV-2 testing) method is Poold Diagnostics' proprietary technology that combines PCR with a combinatorial pooling algorithm to increase diagnostic testing capacity and reduce costs for SARS-CoV-2 screening.

When did the Israeli Ministry of Health approve Poold Diagnostics' method?

In August 2020, the Israeli Ministry of Health approved Poold Diagnostics' pooling-based efficient SARS-CoV-2 testing (P-BEST) method for clinical use.

What was the impact of the P-BEST method's clinical use?

The P-BEST method has been used to screen over 5,000 subjects using only 700 pools, correctly detecting more than 60 positive carriers with no false negatives, demonstrating its efficiency and accuracy.